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1. Introduction 
By using isolated rat islets in a perifusion system, 
5 min exposure to alloxan (20 mg%) in a 1 mg/ml 
glucose medium is shown to produce complete 
inhibition of glucose (5 mglml)-induced insulin 
secretion and this alloxan effect is prevented by 
simultaneous presence of 5 mgjml glucose in 
alloxan medium [l] . The order of potencies of 
hexoses to protect against alloxan toxicity in vitro 
[glucose( 100)>3-0methylglucoseZ=mannose>2- 
deoxyglucose galactose>>Lglucose(O)] does not 
parallel the established order of their insulin-releasing 
action [glucose( 1 OO)>mannose>fructose>>galactose = 
2-deoxyglucose = 3-O-methyl-glucose = L-glucose(O)] 
[l] . To further understand the effect of alloxan, 
phlorizin, an inhibitor of glucose transport, is used 
in the present experiment. Alloxan was shown to 
induce penetration of extracellular marker ([ 14C] 
Mamtitol) into toadfish islet tissue and this effect was 
protected by simultaneous presence of phlorizin 
(0.5 mM) [2]. The interaction of alloxan and 
phlorizin has not been reported so far in isolated islets 
in terms of insulin secretion. 
2. Materials and methods 
More than two hundred islets of Langerhans were 
isolated from one fed male Sprague-Dawley rat 
(200-300 g) by the standard collagenase technique [3] 
The perifusion system utilized was the same as 
reported previously except for the three chambers 
utilized simultaneously: one used for the control and 
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the others as experimental chambers. The chambers 
were maintained at 37’C and perifused at a flow rate 
of 0.7-0.8 ml/min. The perifusate was collected at 
one- or five-minute intervals and the insulin content 
of aliquots was determined by the radioimmunoassay 
and expressed as pU/islet/min [4] . 
Exposure to alloxan: Alloxan monohydrate 
(Sigma Chemical, St. Louis) was dissolved at a concen- 
tration of 20 mg% in previously warmed (37°C) and 
gassed (95% 02, 5% COa) Krebs-Ringer bicarbonate 
medium immediately prior to perifusion. Phlorizin 
solution: Phlorizin (K & K Lab., Hollywood, Calif.) 
was dissolved in l-2 ml of distilled water at 58”C, 
then was made to final concentrations of phlorizin 
(0.5- 10 mM) and glucose (1 mgjml) by adding 
warmed (37°C) bicarbonate medium. 
3. Results 
Glucose-stimulated insulin secretion was tested using a 
2 mg/ml, 3 mg/ml and 5 mg/ml glucose medium. 
Baseline secretion was established by first perifusing 
the islets with a 1 mg/ml glucose medium for 50 min. 
The amount of insulin secretion was parallel to the 
concentrations of glucose with maximal insulin 
secretion occurring in a 5 mglml glucose medium. The 
biphasic secretory profile was evident after perifusing 
with a 5 mglml glucose medium. The first phase 
occurred after 5-7 min, and the second phase 
20-30 min after stimulation (fig.l). Accordingly, the 
following experiments were performed’using a 5 mg/ 
ml glucose medium, which induced the maximal and 
the most prominent biphasic secretory proffie. 
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Fig.1. Glucose-induced insulin secretion was tested by 
simultaneous three chamber perifusion to a 2 mg/ml, 
3 mglml and S.mg/ml glucose medium after obtaining 
baseline secretion by 50 min perifusion with a 1 mglml 
glucose medium. The fiit phase secretion was observed by 
all of the stimulating glucose levels at 5-6 min and the 
second phase was most prominent at 20-30 min perifusion 
by a 5 mg/ml glucose medium. The total insulin secretion by a 
2 mgjml, 3 mg/ml and 5 mg/ml glucose medium was: 
9.0 f 2.7, 19.2 f 4.7, and 24.4 f 2.4 mU/lOO islets/60 min 
respectively. Upper: 2 mg/ml, Middle: 3 mglml and Lower: 
5 mg/ml glucose stimulation. 
Fig.2 shows that a five minute exposure to 10 mM 
phlorizin inhibited both the first and second phases 
of insulin secretion. The biphasic pattern was still 
maintained with a total insulin output of 64% of the 
control (table 1). The presence of alloxan in the 
phlorizin solution yielded exactly the same secretory 
profile with complete abolishment of the alloxan effect 
(20 mg%). 4 mM phlorizin produced similar effects on 
glucose-induced insulin secretion and reversed the 
alloxan toxicity as the same degree as 10 mM (table 1). 
Less than 2 mM concentrations produced less inhibi- 
tion of insulin secretion although there was no direct 
Fig.2. A 5 min exposure to 10 mM phlorizin in a 1 mg/ml 
glucose medium inhibited the subsequent glucoseinduced 
msnlin secretion with decreased but retained biphasic 
profiles. The concomitant presence of alloxan in a mixture 
of phlorizin and glucose yielded exactly the same secretory 
pattern with no effect of alloxan. Upper: Control (broken 
line) and 5 min exposure to 10 mM phlorizin (solid line), 
Lower: 5 min exposure to a mixture of phlorizin and alloxan. 
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Fig3. A 5 min exposure to 0.5 mM phlorizin in a 1 mg/ml 
glucose medium produced’less inhibition of biphasic insulin 
secretory profde. The first phase had already started during 
perifusion with the phlorizin medium. The reversal of the 
alloxan effect was least effective by the 0.5 mM phlorizin 
medium with less prominent secretory phases. Upper: 
Control (broken line) and 5 min exposure to 0.5 mM 
phlorizin (solid line), Lower: 5 min exposure to a mixture 
of phlorizin and aBoxan. 
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Table 1 
Effect of different current ratios of phlorizin on glucose-induced insulin secretions 
5 Min exposure Glucose 5 mglml 
Group Phlorizin Alloxan Insulin secretion aPercent bPercent 
of exp. (mM) (mg%) mU/lOO islets/60 min secretion inhibition 
mean + SEM 
- 
I 0 0 24.23 f 1.12 (4) 100 0 
10 0 15.47 f 1.88 (4) 63.8 36.2 
10 20 15.76 f 1.20 (4) 64.9 35.1 
II 0 0 22.78 f 1.40 (4) 
4 0 15.74 f 1.66’ (4) 69.1 30.9 
4 20 15.59 f 1.56 (4) 68.4 31.6 
III 0 0 21.69 i 0.92 (3) 
2 0 18.79 k 2.18 (3) 86.6 13.4 
2 20 15.26 + 1.75 (3) 70.4 29.6 
IV 0 0 23.16 + 1.48 (3) 
1 0 18.81 f 1.39 (3) 81.2 18.8 
1 20 11.63 * 0.55 (3) 50.2 49.8 
V 0 0 21.22 f 0.64 (4) 
0.5 0 18.41 f 1.13 (4) 86.8 13.2 
0.5 20 5.50 f 0.32 (4) 25.9 74.1 
aThe total insulin secreted with a 5 mg/ml glucose was divided by the control’insulin secretion 
in each group of experiments. 
bPercent inhibition = 100% - percent secretion. 
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dose-dependent fashion of inhibition in the range 
between 2 mM and 0.5 mM (table 1). The reversal of 
alloxan toxicity by phlorizin showed declining 
tendency of protection from 2 mM to 0.5 mM (table 1). 
Fig.3 demqnstrates that a 5 min exposure to 0.5 mM 
phlorizin produced less inhibition of biphasic insulin 
secretory profile. The first phase had already started 
during perifusion with the phlorizin medium (fig.3). 
The reversal of the alloxan effect declined to 25.9% 
by the 0.5 mM phlorizin medium (table 1). 
4. Discussion 
Phlorizin has been widely used to study hexose 
transport by renal tubules [5], yet its action in islet 
tissue is still obscure. Lambert et al. reported that 
the concomitant presence of phlorizin (1 and 2 mM) 
inhibited the glucose (0.25 mg/ml)-stimulated 
insulin release to less than 68% of the control value 
seen in cultured pancreatic explants of fetal rats [6]. 
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Using microdissected islets of obese-hyperglycemic 
mice, Hellman et al. disclosed that the uptake of 
phlorizin occurs rapidly within a 7 min exposure and 
is concentration-dependent up o 5 mM [7 1. Phlorizin 
at concentrations l-5 mM did not modify the insulin 
release stimulated by a 1.8 mg/ml glucose medium, but 
a 10 mM concentration of phlorizin depressed the 
insulin secretion to 56% of the controls [8]. 10 mM 
phlorizin also provided the islets with inhibition to 
glucose transport (100%) and glucose oxidation 
(37%) [8]. 
Thus the rat islets used in this study showed 
different insulin secretion from the diabetic mouse 
islets [8]. The rat islets were more sensitive to low 
concentrations (0.5-2 mM) of phlorizin, yielding 
more than 13% inhibition of insulin secretion with no 
dose-dependent relationship to the increasing concen- 
trations of phlorizin (table 1). Whereas the hyper- 
glycemic mouse islets were reported to produce less 
than 8% of inhibition of insulin secretion by con- 
comitant presence of 1 and 5 mM phlorizin in a 
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1.8 mg/ml glucose medium [8] . This difference is 
probably due to the difference of sensitivity to 
phlorizin between ormoglycemic rat islets and hyper- 
glycemic mouse islets. 
As for the reversal of alloxan effect in rat islets, 
10;4 and 2 mM phlorizin retained insulin secretion 
above 65% of the control while 1 and 0.5 mM 
produced 50% and 25% of protection respectively 
with dose-dependent declining protection against 
alloxan (table 1). 
Phlorizin (S-l 5 mM) alone was shown to 
stimulate insulin secretion in the absence of glucose, 
and its stimulatory effect was inhibited by manno- 
heptulose, suggesting that phlorizin exerts its effect 
by the same system which recognizes glucose as an 
insulin secretagogue [ 71 . 
The results in this paper showed the two different 
degrees of inhibition of glucose-induced insulin 
secretion between 5-10 mM and 0.5-2 mM of 
phlorizin yet both the first and second phases of 
secretory profile were distinctively preserved. This 
effect of phlorizin is in contrast o that of manno- 
heptulose, the latter inhibits completely and 
specifically the first phase secretion alone [l] . 
The glucose-stimulated insulin secretion is accom- 
panied by electrical activity [9] . The different effects 
of phlorizin and mannoheptulose may be explained 
by this respective ffect on the electrical activity. 
Phlorizin (10 mM) causes apartial inhibition whereas 
mannoheptulose (20 mM) causes complete inhibition 
of electrical activity [lo] . 
Phlorizin appears to have at least two different 
effects. High concentrations of phlorizin inhibit meta- 
bolism and hence depress energy-yielding reaction, 
whereas an action on glucose transport is demonstrable 
at far lower concentrations [5] . Thus, phlorizin at 
0.5 mM concentration has little effect on glucose 
metabolism but it interacts with the glucose transport 
site to competitively inhibit glucose transport [2]. 
This low concentration i hibits glucose-induced 
insulin secretion more potently than its effect to 
interact against the alloxan toxicity, probably acting 
at the common site of transport for glucose, alloxan 
and phlorizin (table 1). It is also in accord with the 
fact that protection against alloxan is provided by 
non-metabolizable h xoses, which share the same 
transport site as glucose [l] . 
More recently, McDaniel et al. reported that 
alloxan did not exert an effect on permeability to 
extracellular markers (sucrose, D-mannitol or 
Lglucose) and that alloxan did not alter the rate of 
D-glucose or 3-U-methyl-glucose transport into rat 
islets [ 111. If this is true, the primary site of action 
of alloxan is likely a glucoreceptor site, which is also 
shared by phlorizin at least in part. It is still not 
known how a glucoreceptor site separate from a 
transport site on the beta-cell membrane and how two 
sites interact each other. 
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